Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin for sialorrhea in amyotrophic lateral sclerosis
2010-023161-21Phase 2Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of botulinum toxin type A in amyotrophic lateral sclerosis (ALS), sponsored by Hospices Civils de Lyon. Primary endpoint: Functional discomfort due to salivary disorder at 1 month. Started Sep 2011; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2010-023161-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023161-21.